Efficacy of concurrent utilization of estradiol valerate and Chinese herbal capsule in managing premature ovarian failure

Lu Sun, Xiaodong Fan, Qian Chen, Guoyan Liu

Abstract

The objective of this study was to examine the efficacy of the concurrent utilization of estradiol valerate and kuntai capsule (a Chinese herbal preparation) in addressing premature ovarian failure (POF) and its ramifications for ovarian hemodynamics and sex hormone levels. A retrospective study of 104 patients with POF was conducted, dividing them into control (n=50) and observation groups (n=54). The control group received estradiol valerate, while the observation group received estradiol valerate and KunTai capsules over 12 weeks. Clinical effectiveness, ovarian pulsatility index (PI), resistance index (RI), hormone levels, ovarian function, and adverse reactions were analyzed. The observation group showed significantly improved PI, RI, LH, FSH, E2 levels, and ovarian function in relative to the control group (P<0.05). We conclude that the concurrent use of estradiol valerate and KunTai capsules improves ovarian hemodynamics and hormone levels, offering significant clinical benefits.

Full Text:

PDF

References

Wang L, Wang L, Wang R, Zhang X, Wang Q and Zhang

Y. Endometrial stem cell-derived exosomes repair

cisplatin-induced premature ovarian failure via

Hippo signaling pathway. Heliyon, 2024, 10(10):

e31639.DOI: 10.1016/j.heliyon.2024.e31639

Kuchakzadeh F, Ai J and Ebrahimi-Barough S. Tissue

engineering and stem cell-based therapeutic

strategies for premature ovarian insufficiency.

Regen Ther, 2024, 25: 10-23.DOI:

1016/j.reth.2024.01.001

Zhao X, Shi W, Liu X, Tang Z, Sun J and Zhang H.

Emerging trends and research priorities in

premature ovarian insufficiency genes: a

bibliometric and visualization study. Gynecol

Endocrinol, 2023, 39(1): 2283033.DOI:

1080/09513590.2023.2283033

Huang X C, Jiang Y N, Bao H J, Sun X R, Zhao L M and

Li S H. Role and Mechanism of Epigenetic

Regulation in the Aging of Germ Cells: Prospects

for Targeted Interventions. Aging Dis, 2024.

Evangelinakis N, Geladari E V, Geladari C V,

Papadopoulos A, Georgiou E and Pavlakis K. The

influence of environmental factors on premature

ovarian insufficiency and ovarian aging.

Maturitas, 2024, 179: 107871.DOI:

1016/j.maturitas.2023.107871

Cai L, Zong D K, Tong G Q, Wang Y, Chen Y and Li H

J. Apoptotic mechanism of premature ovarian

failure and rescue effect of Traditional Chinese

Medicine: a review. J Tradit Chin Med, 2021,

(3): 492-498.DOI:

19852/j.cnki.jtcm.2021.03.018

Fu Y X, Ji J, Shan F, Cheng J X, Wu Q L and Zhang X Y.

Human mesenchymal stem cell treatment of

premature ovarian failure: new challenges and

opportunities. Stem Cell Res Ther, 2021, 12(1):

DOI: 10.1186/s13287-021-02238-y

Armeni E, Paschou S A, Goulis D G, Lambrinoudaki I,

Bili E and Alexandrou V. Hormone therapy

regimens for managing the menopause and

premature ovarian insufficiency. Best Pract Res

Clin Endocrinol Metab, 2021, 35(6): 101561.DOI:

1016/j.beem.2021.101561

Lin J, Wu D, Jia L, Song F, Chen Y and Chen Y. The

Treatment of Complementary and Alternative

Medicine on Premature Ovarian Failure. Evid

Based Complement Alternat Med, 2021, 2021:

DOI: 10.1155/2021/6677767

Ma Q, Tan Y, Mo G and Fan Z. Effectiveness of

Cotreatment with Kuntai Capsule and Climen for

Premature Ovarian Failure: A Meta-Analysis.

Evid Based Complement Alternat Med, 2020,

: 4367359.DOI: 10.1155/2020/4367359

Liu F X and Sun Y. Identification of the active ingredients

and pharmacological effects of Kuntai capsules in

the treatment of primary ovarian insufficiency: A

review. Medicine (Baltimore), 2023, 102(21):

e33884.DOI: 10.1097/MD.0000000000033884

Haverinen A, Luiro K, Kangasniemi M H, Vainio M,

Uotila J and Huhtaniemi I. Estradiol Valerate vs

Ethinylestradiol in Combined Oral

Contraceptives: Effects on the Pituitary-Ovarian

Axis. J Clin Endocrinol Metab, 2022, 107(7):

e3008-e3017.DOI: 10.1210/clinem/dgac186

Haverinen A H, Luiro K M, Szanto T, Klemetti M,

Kangasniemi M H and Vainio M. Combined oral

contraceptives containing estradiol valerate vs

ethinylestradiol on coagulation: A randomized

clinical trial. Acta Obstet Gynecol Scand, 2022,

(10): 1102-1111.DOI: 10.1111/aogs.14395

Slopień R and Warenik-Szymankiewicz A. Premature

ovarian failure: diagnosis and treatment. Clin Exp

Obstet Gynecol, 2014, 41(6): 659-61.DOI:

12891/ceog2014659.2014

Kou M J, Ding X F, Chen J X, Zhao Y, Yu H and Zhang

L. Traditional Chinese Medicine Combined with

Hormone Therapy to Treat Premature Ovarian

Failure: A Meta-Analysis of Randomized

Controlled Trials. Afr J Tradit Complement Altern

Med, 2016, 13(5): 160-169.DOI:

4314/ajtcam.v13i5.21

Zhong H Z, Li M Y, Yin X L, Liu Y X, Xu M and Feng

W J. Chinese patent medicines combined with

hormone replacement therapy for premature

ovarian failure: A Bayesian network metaanalysis. Front Med (Lausanne), 2022, 9:

DOI: 10.3389/fmed.2022.1043390

Xu B H, Li M Q and Luo Y J. [Treatment of premature

ovarian failure patients by bushen tiaojing recipe

combined hormone replacement therapy: a

clinical observation]. Zhongguo Zhong Xi Yi Jie

He Za Zhi, 2013, 33(10): 1332-5.DOI:

7666/d.y2167501

Bauerfeind A, Von Stockum S, Boehnke T, Böhler K,

Richter S and Schmidt R. Venous

Thromboembolic Risk of Estradiol ValerateDienogest Compared with Ethinyl EstradiolLevonorgestrel Combined Oral Contraceptives.

Obstet Gynecol, 2024, 143(3): 431-434.DOI:

1097/AOG.0000000000005174

Feng W, Nie L, Wang X, Zhang H, Li W and Qiao J.

Effect of Oral versus Vaginal Administration of

Estradiol and Dydrogesterone on the Proliferative

and Secretory Transformation of Endometrium in

Patients with Premature Ovarian Failure and

Preparing for Assisted Reproductive Technology.

Drug Des Devel Ther, 2021, 15: 1521-1529.DOI:

2147/DDDT.S305848

Li X, Ma J, Guo L, Zhang Y, Zhou F and Han Y.

Identification of Bioactive Compounds and

Potential Mechanisms of Kuntai Capsule in the

Treatment of Polycystic Ovary Syndrome by

Integrating Network Pharmacology and

Bioinformatics. Oxid Med Cell Longev, 2022,

: 3145938.DOI: 10.1155/2022/3145938

Refbacks

  • There are currently no refbacks.